Update 2021: COVID-19 aus Sicht der Intensivmedizin

COVID-19 stellt weiterhin hohe Ansprüche an die Intensivmedizin. Im Verlauf der Pandemie gelang es immer mehr, für viele Herausforderungen Lösungen zu finden. Dennoch bleiben Fragen offen, besonders was die personelle Situation auf den Intensivstationen angeht. Dieser Beitrag stellt eine Aktualisierung insbesondere der Erkenntnisse zu Diagnostik und Therapie der letzten Monate aus Sicht der Intensivmedizin dar.

Abstract

COVID-19 continues to challenge health-care systems and ICUs around the globe more than one year into the pandemic and in spite of all advances in diagnosis and treatment of the disease caused by the novel SARS-CoV-2. Many open questions remain concerning optimal medical therapy, respiratory management and resource allocation, particuly in times of limited available health care personell. In the following short article, we summarized current knowlegde on management of COVID-19 in the ICU.

Schlüsselwörter

Corona - Pandemie - COVID-19 - ARDS - SARS-CoV2

Key words

Corona - pandemia - COVID-19 - ARDS - SARS-CoV2

Publikationsverlauf

Artikel online veröffentlicht:
13. Juli 2021

• Literatur

• 1 Wang W, Xu Y, Gao R. et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA – J. Am. Med. Assoc 2021; 323 (18) 2020-2021
• 2 Kluge S, Janssens U, Welte T. et al. Empfehlungen zur intensivmedizinischen Therapie von Patienten mit COVID-19. Med Klin Intensivmed Notfmed 2020; 115: 175-177
• 3 Manson JJ, Crooks C, Naja M. et al. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. Lancet Rheumatol 2020; 9913 (20) e594-e602
• 4 Dargent A, Chatelain E, Kreitmann L. et al Lung ultrasound score to monitor COVID-19 pneumonia progression in patients with ARDS. PLoS ONE 2020; 15 (07) e0236312
• 5 Karagiannidis C, Mostert C, Hentschker C. et al. Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. Lancet Respir Med 2020; 8: 853-862
• 6 Prescott HC, Rice TW. Corticosteroids in COVID-19 ARDS: Evidence and Hope During the Pandemic. JAMA 2020; 324 (13) 1292-1295
• 7 The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group Authors and Members of the Writing Committee. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 A Meta-analysis. JAMA – J. Am. Med. Assoc 2020; 324 (13) 1330-1341
• 8 Mouncey PR, Rowan KM, Nichol AD. et al. N Engl J Med 2021; 384 (16) 1491-1502
• 9 Recovery Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021; 397 (10285): 1637-1645
• 10 Barbaro RP, Maclaren G, Boonstra PS. et al. Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry. Lancet 2020; 396 (10257): 1071-1078